ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: ACS Estimates 502,000 U.S. Cancer Deaths, 178,000 Avoidable With Early Diagnosis

March 17, 1989

NIH director would have broad authority over institute budgets in proposed bill.

July 22, 2005

In Brief: Plastic Surgeon James French Named to NCAB; Clinton Re-Appoints Nienhuis

April 11, 2000

In Brief: Comis Named ECOG Chairman; Long Joins Capitol Associates; Chabner Day In Shelbyville

April 14, 1995

In Brief: ACS Board Names McGinnis Prsident; Fuller Re-Elected chairman; Lenhard Is Vice President

November 25, 1994

First Panel Meeting On Centers Generates Possible Recommendations For Core Grant Guideline Changes

April 6, 1984